Hanyang Med Rev.  2013 May;33(2):97-103. 10.7599/hmr.2013.33.2.97.

Studies on In Vivo Function of Peroxiredoxins in Knockout Mice

Affiliations
  • 1Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea. dyyu10@kribb.re.kr

Abstract

Peroxiredoxins (Prxs) are a family of antioxidant proteins that reduce peroxide levels by using reducing agents such as thioredoxin. These proteins were characterized to have a number of cellular functions, including cell proliferation and differentiation and protection of specific proteins from oxidative damage. Thus, it is important to clarify the physiological role of Prxs by generating mouse models deficient in each Prx to better understand the in vivo function of Prxs. We have generated and characterized mice deficient in Prx I and II that are abundantly expressed in almost all types of cells. The Prx II-/- mice were healthy in appearance and fertile, however showed several pathophysiological disorders. Using the mice, we found that Prx II is an essential antioxidant enzyme that prevents oxidative stress in erythropoiesis, protects against endotoxin-induced lethal shock, regulates platelet-derived growth factor signaling and angiogenesis, inhibits cellular senescence, preserves cognitive function against age-linked hippocampal oxidative damage and exacerbates tumorigenesis in a liver cancer mouse model. The Prx I-/- mice were also healthy in appearance and fertile like Prx II-/- mice. With the mice, we found that Prx I suppresses K-ras-driven lung tumorigenesis by opposing the redox-sensitive extracellular-signal-regulated kinase/cyclin D1 pathway and plays concerted action with sulfiredoxin in preventing against alcohol-induced oxidative injury in the mouse liver. The results obtained suggest that Prx I and II are essential antioxidant enzymes for maintaining redox homeostasis in mice.

Keyword

Peroxiredoxin; Knockout Mouse; Oxidation-Reduction; Antioxidants

MeSH Terms

Animals
Antioxidants
Cell Aging
Cell Proliferation
Cell Transformation, Neoplastic
Erythropoiesis
Homeostasis
Humans
Liver
Liver Neoplasms
Lung
Mice
Mice, Knockout
Oxidation-Reduction
Oxidative Stress
Peroxiredoxins
Platelet-Derived Growth Factor
Proteins
Reducing Agents
Shock
Thioredoxins
Antioxidants
Peroxiredoxins
Platelet-Derived Growth Factor
Proteins
Reducing Agents
Thioredoxins

Cited by  1 articles

Do Reactive Oxygen Species Cause Aging?
Seong Eon Ryu
Hanyang Med Rev. 2013;33(2):75-76.    doi: 10.7599/hmr.2013.33.2.75.


Reference

1. Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem. 1999; 32:595–603.
Article
2. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009; 8:579–591.
Article
3. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol. 2005; 17:183–189.
Article
4. Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci U S A. 1994; 91:7017–7021.
Article
5. Rhee SG, Kang SW, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life. 2001; 52:35–41.
Article
6. Hofmann B, Hecht HJ, Flohe L. Peroxiredoxins. Biol Chem. 2002; 383:347–364.
Article
7. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003; 28:32–40.
Article
8. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem. 1998; 273:6297–6302.
Article
9. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. J Biol Chem. 1997; 272:30615–30618.
Article
10. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet. 1995; 11:376–381.
Article
11. Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A. 1996; 93:9782–9787.
Article
12. Ikegami T, Suzuki Y, Shimizu T, Isono K, Koseki H, Shirasawa T. Model mice for tissue-specific deletion of the manganese superoxide dismutase (MnSOD) gene. Biochem Biophys Res Commun. 2002; 296:729–736.
Article
13. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996; 13:43–47.
Article
14. Ho YS, Magnenat JL, Bronson RT, Cao J, Gargano M, Sugawara M, et al. Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia. J Biol Chem. 1997; 272:16644–16651.
Article
15. Lee TH, Kim SU, Yu SL, Kim SH, Park DS, Moon HB, et al. Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood. 2003; 101:5033–5038.
Article
16. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003; 424:561–565.
Article
17. Li L, Shoji W, Takano H, Nishimura N, Aoki Y, Takahashi R, et al. Increased susceptibility of MER5 (peroxiredoxin III) knockout mice to LPS-induced oxidative stress. Biochem Biophys Res Commun. 2007; 355:715–721.
Article
18. Li L, Shoji W, Oshima H, Obinata M, Fukumoto M, Kanno N. Crucial role of peroxiredoxin III in placental antioxidant defense of mice. FEBS Lett. 2008; 582:2431–2434.
Article
19. Huh JY, Kim Y, Jeong J, Park J, Kim I, Huh KH, et al. Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal. 2012; 16:229–243.
Article
20. Lim MJ, Chae HZ, Rhee SG, Yu DY, Lee KK, Yeom YI. The type II peroxiredoxin gene family of the mouse: molecular structure, expression and evolution. Gene. 1998; 216:197–205.
Article
21. Han YH, Kwon T, Kim SU, Ha HL, Lee TH, Kim JM, et al. Peroxiredoxin I deficiency attenuates phagocytic capacity of macrophage in clearance of the red blood cells damaged by oxidative stress. BMB Rep. 2012; 45:560–564.
Article
22. Kwon TH, Han YH, Hong SG, Lee DJ, Ha HL, Kang SW, et al. Reactive oxygen species mediated DNA damage is essential for abnormal erythropoiesis in peroxiredoxin II(-/-) mice. Biochem Biophys Res Commun. 2012; 424:189–195.
Article
23. Han YH, Kim SU, Kwon TH, Lee DS, Ha HL, Park DS, et al. Peroxiredoxin II is essential for preventing hemolytic anemia from oxidative stress through maintaining hemoglobin stability. Biochem Biophys Res Commun. 2012; 426:427–432.
Article
24. Macip S, Igarashi M, Fang L, Chen A, Pan ZQ, Lee SW, et al. Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO J. 2002; 21:2180–2188.
Article
25. Han YH, Kim HS, Kim JM, Kim SK, Yu DY, Moon EY. Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence. FEBS Lett. 2005; 579:4897–4902.
Article
26. Kim SU, Jin MH, Kim YS, Lee SH, Cho YS, Cho KJ, et al. Peroxiredoxin II preserves cognitive function against age-linked hippocampal oxidative damage. Neurobiol Aging. 2011; 32:1054–1068.
Article
27. Choi MH, Lee IK, Kim GW, Kim BU, Han YH, Yu DY, et al. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature. 2005; 435:347–353.
Article
28. Kang DH, Lee DJ, Lee KW, Park YS, Lee JY, Lee SH, et al. Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell. 2011; 44:545–558.
Article
29. Park JG, Yoo JY, Jeong SJ, Choi JH, Lee MR, Lee MN, et al. Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice. Circ Res. 2011; 109:739–749.
Article
30. Rhee SG, Bae YS, Lee SR, Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci STKE. 2000; 2000:pe1.
Article
31. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest. 2003; 111:769–778.
Article
32. Rhee SG, Chang TS, Bae YS, Lee SR, Kang SW. Cellular regulation by hydrogen peroxide. J Am Soc Nephrol. 2003; 14:S211–S215.
Article
33. Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol. 2004; 172:2522–2529.
Article
34. Yang CS, Lee DS, Song CH, An SJ, Li S, Kim JM, et al. Roles of peroxiredoxin II in the regulation of proinflammatory responses to LPS and protection against endotoxin-induced lethal shock. J Exp Med. 2007; 204:583–594.
Article
35. Zhang B, Wang Y, Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett. 2009; 286:154–160.
Article
36. Shiota M, Yokomizo A, Kashiwagi E, Takeuchi A, Fujimoto N, Uchiumi T, et al. Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. Free Radic Biol Med. 2011; 51:78–87.
Article
37. Stresing V, Baltziskueta E, Rubio N, Blanco J, Arriba M, Valls J, et al. Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene. 2013; 32:724–735.
Article
38. Neumann CA, Cao J, Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle. 2009; 8:4072–4078.
Article
39. Kim SU, Hwang CN, Sun HN, Jin MH, Han YH, Lee H, et al. Peroxiredoxin I is an indicator of microglia activation and protects against hydrogen peroxide-mediated microglial death. Biol Pharm Bull. 2008; 31:820–825.
Article
40. Bae JY, Ahn SJ, Han W, Noh DY. Peroxiredoxin I and II inhibit H2O2-induced cell death in MCF-7 cell lines. J Cell Biochem. 2007; 101:1038–1045.
Article
41. Butterfield LH, Merino A, Golub SH, Shau H. From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. Antioxid Redox Signal. 1999; 1:385–402.
Article
42. Fujii J, Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep. 2002; 7:123–130.
Article
43. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology. 2006; 11:269–275.
Article
44. Park YH, Kim SU, Lee BK, Kim HS, Song IS, Shin HJ, et al. Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway. Antioxid Redox Signal. 2012.
Article
45. Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, Hardingham GE. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells. 2009; 27:279–282.
Article
46. Bae SH, Sung SH, Cho EJ, Lee SK, Lee HE, Woo HA, et al. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology. 2011; 53:945–953.
Article
47. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology. 2006; 43:S63–S74.
Article
48. Seong JK, editor. DASAN 2012 Conference for Mouse Phenogenomics. 2012 Sep 23-25; Seogwipo, Jeju, Korea.
Full Text Links
  • HMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr